公开(公告)号：BRPI0519570A2

公开(公告)日：2009-01-27

申请号：BRPI0519570

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

Abstract: We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the interindividual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

公开(公告)号：HK1117571A1

公开(公告)日：2009-01-16

申请号：HK08108714

申请日：2008-08-07

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q20060101

Abstract: We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the interindividual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

公开(公告)号：PL2016198T3

公开(公告)日：2013-12-31

申请号：PL07797432

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  SHEN CHIH-LUNG ,  CHANG CHI-FENG ,  LIN HSIN-YU ,  CHEN WEI-HSUAN

IPC: C12Q1/68

公开(公告)号：AU2013219191A1

公开(公告)日：2013-09-12

申请号：AU2013219191

申请日：2013-08-21

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  CHEN YUAN-TSONG ,  HUNG SHUEN-LU ,  CHEN WEI-HSUAN ,  LIN HSIN-YU

IPC: C12Q1/68

Abstract: The present invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for 5 developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).

公开(公告)号：SI1697539T1

公开(公告)日：2010-11-30

申请号：SI200431510

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

公开(公告)号：PT1697539E

公开(公告)日：2010-10-04

申请号：PT04776718

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

公开(公告)号：AT476524T

公开(公告)日：2010-08-15

申请号：AT04776718

申请日：2004-06-18

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  HUNG SHUEN-IU ,  CHUNG WEN-HUNG ,  WU JER-YUARN

IPC: C12Q1/68 ,  G01N33/94

公开(公告)号：AT470725T

公开(公告)日：2010-06-15

申请号：AT05855433

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

Abstract: We discovered that a polymorphism in the promoter of the VKORCI gene is associated with warfarin sensitivity. This polymorphism can explain both the interindividual and inter-ethnic differences in warfarin dose requirements. Furthermore, the polymorphism is also associated with promoter activity. Thus, the promoter sequence or activity of the VKORCI gene of a subject can be used to predict how much warfarin should be prescribed for the subject. Relevant methods and compositions are provided.

公开(公告)号：NZ556461A

公开(公告)日：2009-12-24

申请号：NZ55646105

申请日：2005-12-21

Applicant: ACADEMIA SINICA

Inventor： CHEN YUAN-TSONG ,  YUAN HSIANG-YU ,  CHEN JIN-JER

IPC: C12Q1/68

Abstract: Disclosed is a method of determining the dose range of warfarin for a subject, comprising investigating the single nucleotide polymorphism (SNP) at the 3673 position of SEQ ID NO: 1 in the subject, determining whether the subject is warfarin sensitive or resistant based on the SNP at the 3673 position, wherein homozygous AA, heterozygous AG, and homozygous GG at this position indicate that the patient is warfarin sensitive, intermediate sensitive, and resistant, respectively; and predicting a warfarin dosage range based on the warfarin sensitivity/resistance of the subject.

公开(公告)号：CA2651954A1

公开(公告)日：2007-11-22

申请号：CA2651954

申请日：2007-05-11

Applicant: ACADEMIA SINICA ,  PHARMIGENE INC

Inventor： CHEN WEI-HSUAN ,  LIN HSIN-YU ,  CHANG CHI-FENG ,  SHEN CHIH-LUNG ,  HUNG SHUEN-LU ,  CHEN YUAN-TSONG

IPC: C12Q1/68 ,  C12P19/34 ,  C12Q1/02

Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out t his method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the pres ence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B* 4601).